Skip to main content

ENGLISH · EVIDENCE OVERVIEW

Setmelanotide
evidence profile

Melanocortin-4 receptor agonist. This is a concise English overview, not a full translation. Read the evidence boundaries and original sources below; the detailed study and risk discussion remains available in Thai.

What do Class, Grade and Risk mean?

Setmelanotide: conceptual scientific illustration for Metabolic / GLP-1
VISUAL GUIDE · Setmelanotide

Metabolic / GLP-1

Category-level conceptual illustration, not a map of this molecule's receptor targets. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

An MC4 receptor agonist authorised for narrowly defined genetic and hypothalamic obesity contexts; these approvals explicitly do not extend to general obesity.

01

ENTITY FACTS

What should readers identify first?

MOLECULESetmelanotide
PHARMACOLOGYMelanocortin-4 receptor agonist
PRIMECORE CLASSA
EVIDENCE GRADEA
RESEARCH TOPICMetabolic / GLP-1
LAST REVIEWED2026-08-27

What remains unknown?

English translation is not yet verified for 3 excerpt(s). This is a language gap, not an absence of risks or uncertainty.

Read original excerpts (Thai / mixed language)
  • ผลนอกโรคและประชากรที่ฉลากระบุ
  • ความปลอดภัยระยะยาวในประชากรที่กว้างขึ้น
  • สถานะผลิตภัณฑ์ในประเทศไทย

What limits these conclusions?

English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.

Read original excerpts (Thai / mixed language)
  • หลักฐานสำคัญใน POMC/LEPR deficiency มีผู้เข้าร่วมจำนวนน้อยตามธรรมชาติของโรคหายาก และได้รับทุนจากผู้พัฒนา ผลของ BBS, genetic deficiency และ acquired hypothalamic obesity ต้องอ่านแยกกัน

This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.

02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.

Where can I check the evidence?

Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf
  2. https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree
  3. https://pubmed.ncbi.nlm.nih.gov/33137293/
  4. https://pubmed.ncbi.nlm.nih.gov/36356613/
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is Setmelanotide?

Setmelanotide is described pharmacologically as Melanocortin-4 receptor agonist. An MC4 receptor agonist authorised for narrowly defined genetic and hypothalamic obesity contexts; these approvals explicitly do not extend to general obesity.

Does Setmelanotide have strong evidence?

PrimeCoreBio records Evidence Grade A. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is Setmelanotide approved everywhere?

No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

Contact PrimeCoreBio

Choose a contact channel

General information only · No sales or medical advice